Próstata: Lista de 52 Estudos Científicos que Sustentam os Tratamentos Naturais e Convencionais

Para sua melhor informação, aqui tem uma lista de Estudos Científicos sobre HBP, Prostatite e Cancro da Próstata, que este Blog consulta, entre outra informações

A partir dos 40 anos, a próstata passa a ser uma das maiores preocupações de saúde do homem. Sintomas como aumento da frequência urinária, dificuldade em iniciar a micção, jato urinário fraco ou acordar várias vezes durante a noite para urinar não devem ser encarados como “normais da idade”, mas sim como sinais de alerta que merecem atenção informada e responsável.

A realidade é simples: problemas como a hiperplasia benigna da próstata (HBP), a prostatite e até o cancro da próstata partilham sintomas semelhantes nas fases iniciais, o que leva muitos homens a ignorar os sinais ou a adiar decisões importantes. No entanto, a ciência médica tem vindo a estudar estas condições de forma aprofundada há décadas, produzindo um volume significativo de evidência clínica e laboratorial que ajuda a compreender as causas, os mecanismos envolvidos e as opções de intervenção mais eficazes.

Este artigo reúne 52 estudos científicos de referência, publicados em revistas médicas internacionais, que analisam a saúde da próstata sob várias perspetivas: sintomas urinários, inflamação, alterações hormonais, envelhecimento masculino e abordagens terapêuticas, incluindo estratégias nutricionais e naturais com suporte científico.

O objetivo deste blog é claro: oferecer ao leitor informação rigorosa, acessível e baseada em evidência, para que cada homem possa tomar decisões conscientes sobre a sua saúde prostática, em vez de agir por medo, desinformação ou resignação.

Segue a lista:

1. Available at: http://www.cancer.gov/types/prostate/understanding-prostate-changes. Accessed March 9, 2016.
2. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(3):248-57.
3. Suter A, Saller R, Riedi E, et al. Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial. Phytother Res. 2013;27(2):218-26.
4. Zhan XX, Shang XJ, Huang YF. Application of saw palmetto fruit extract in the treatment of prostate diseases. Zhonghua Nan Ke Xue. 2015;21(9):841-6.
5. Fong YK, Milani S, Djavan B. Role of phytotherapy in men with lower urinary tract symptoms. Curr Opin Urol. 2005;15(1):45-8.
6. Engelmann U, Walther C, Bondarenko B, et al. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittelforschung. 2006;56(3):222-9.
7. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002(3):Cd001423.
8. Boyle P, Robertson C, Lowe F, et al. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int. 2004;93(6):751-6.
9. Allkanjari O, Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci. 2015;126:42-56.
10. Tacklind J, MacDonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009(2):Cd001423.
11. Chrubasik JE, Roufogalis BD, Wagner H, et al. A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine. 2007;14(7-8):568-79.
12. Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother. 2005;5(4):1-11.
13. Moradi HR, Erfani Majd N, Esmaeilzadeh S, et al. The histological and histometrical effects of Urtica dioica extract on rat’s prostate hyperplasia. Vet Res Forum. 2015;6(1):23-9.
14. Oelke M, Berges R, Schlafke S, et al. Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies. World J Urol. 2014;32(5):1149-54.
15. Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int. 2000;86(4):439-42.
16. Lopatkin N, Sivkov A, Schlafke S, et al. Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms--long-term follow-up of a placebo-controlled, double-blind, multicenter trial. Int Urol Nephrol. 2007;39(4):1137-46.
17. Shenouda NS, Sakla MS, Newton LG, et al. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocrine. 2007;31(1):72-81.
18. Breza J, Dzurny O, Borowka A, et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin. 1998;14(3):127-39.
19. Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology. 1999;54(3):473-8.
20. Wilt T, Ishani A, Mac Donald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002(1):Cd001044.
21. Vahlensieck W, Theurer C, Pfitzer E, et al. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int. 2015;94(3):286-95.
22. Hong H, Kim CS, Maeng S. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutr Res Pract. 2009;3(4):323-7.
23. MacDonald R, Ishani A, Rutks I, et al. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000;85(7):836-41.
24. Zhang W, Wang X, Liu Y, et al. Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia. J Med Food. 2008;11(2):207-14.
25. Mariani S, Lionetto L, Cavallari M, et al. Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Int J Mol Sci. 2014;15(1):1433-40.
26. Available at: http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Accessed March 14, 2016.
27. Available at: http://www.cancer.net/cancer-types/prostate-cancer/statistics. Accessed March 15, 2016.
28. Borel P, Desmarchelier C, Nowicki M, et al. Lycopene bioavailability is associated with a combination of genetic variants. Free Radic Biol Med. 2015;83:238-44.
29. Holzapfel NP, Holzapfel BM, Champ S, et al. The potential role of lycopene for the prevention and therapy of prostate cancer: from molecular mechanisms to clinical evidence. Int J Mol Sci. 2013;14(7):14620-46.
30. Grainger EM, Hadley CW, Moran NE, et al. A comparison of plasma and prostate lycopene in response to typical servings of tomato soup, sauce or juice in men before prostatectomy. Br J Nutr. 2015;114(4):596-607.
31. Wang Y, Jacobs EJ, Newton CC, et al. Lycopene, tomato products and prostate cancer-specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study-II Nutrition Cohort. Int J Cancer. 2016.
32. Chen P, Zhang W, Wang X, et al. Lycopene and risk of prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(33):e1260.
33. Assar EA, Vidalle MC, Chopra M, et al. Lycopene acts through inhibition of IkappaB kinase to suppress NF-kappaB signaling in human prostate and breast cancer cells. Tumour Biol. 2016.
34. Larre S, Camparo P, Comperat E, et al. Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures. Asian J Androl. 2012;14(3):499-504.
35. El Gaafary M, Buchele B, Syrovets T, et al. An alpha-acetoxy-tirucallic acid isomer inhibits Akt/mTOR signaling and induces oxidative stress in prostate cancer cells. J Pharmacol Exp Ther. 2015;352(1):33-42.
36. Pang X, Yi Z, Zhang X, et al. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res. 2009;69(14):5893-900.
37. Lu M, Xia L, Hua H, et al. Acetyl-keto-beta-boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells. Cancer Res. 2008;68(4):1180-6.
38. Buchele B, Zugmaier W, Estrada A, et al. Characterization of 3alpha-acetyl-11-keto-alpha-boswellic acid, a pentacyclic triterpenoid inducing apoptosis in vitro and in vivo. Planta Med. 2006;72(14):1285-9.
39. Yuan HQ, Kong F, Wang XL, et al. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem Pharmacol. 2008;75(11):2112-21.
40. Demark-Wahnefried W, Robertson CN, Walther PJ, et al. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology. 2004;63(5):900-4.
41. Demark-Wahnefried W, Polascik TJ, George SL, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3577-87.
42. Cui Y, Winton MI, Zhang ZF, et al. Dietary boron intake and prostate cancer risk. Oncol Rep. 2004;11(4):887-92.
43. Gallardo-Williams MT, Chapin RE, King PE, et al. Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice. Toxicol Pathol. 2004;32(1):73-8.
44. Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents. 2008;31 Suppl 1:S112-6.
45. Monden K, Tsugawa M, Ninomiya Y, et al. A Japanese version of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI, Okayama version) and the clinical evaluation of cernitin pollen extract for chronic non-bacterial prostatitis. Nihon Hinyokika Gakkai Zasshi. 2002;93(4):539-47.
46. Potts JM. Therapeutic options for chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2005;6(4):313-7.
47. Wagenlehner FM, Schneider H, Ludwig M, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56(3):544-51.
48. Cai T, Wagenlehner FM, Luciani LG, et al. Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. Exp Ther Med. 2014;8(4):1032-8.
49. Iwamura H, Koie T, Soma O, et al. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urol. 2015;15:120.
50. Available at: http://www.rxlist.com/flomax-drug/side-effects-interactions.htm. Accessed Mach 17, 2016.
51. Ansari MS, Gupta NP. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int. 2003;92(4):375-8; discussion 8.
52. Zhang X, Wang Q, Neil B, et al. Effect of lycopene on androgen receptor and prostate-specific antigen velocity. Chin Med J (Engl). 2010;123(16):2231-6